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Rheumatoid Arthritis
Ana Vigil RN,BSN,CCRN
Otterbein University, Westerville, Ohio
Signs & Symptoms

Introduction
•

•

•

•

•

•

The topic of Rheumatoid arthritis
(RA) was chosen as this disease
process affects up to 1% of the U.S.
population causing disability and
early mortality (Mayo Clinic, 2017).
Advanced practice providers (APPs)
are able to detect and diagnosis RA
early on before damage to patient’s
joints occur (Riley et al., 2017).
As of 2017, there is an anticipated
increase in demand over the next
decade for health care professionals
to be able to detect and develop
treatment plans for patients with
RA (Riley et al., 2017).
Studies have shown that failing to
recognize early or more insidious
symptoms can hinder swift referral
to a Rheumatologist and initiation of
treatment (Riley et al., 2017).
Over the past 20 years, more than
10 new medications for RA have
been developed and approved by
the FDA. These new drugs have
improved outcomes for patients
diagnosed with RA, but can cause
decisions about treatment plans to
be more complex (Mayo Clinic,
2017).
As a future Nurse Practitioner (NP),
there is a high likelihood of
encountering and diagnosing a
patient with this disease process.

About RA
•

•

•

•

RA is an immune mediated
inflammatory disease where
your immune system attacks
the lining of your joints causing
swelling and inflammation
(Barton et al., 2016).
RA typically affects the small
joints in your hands and feet
first, causing pain and stiffness
that can develop into
permanent damage and
deformity if left untreated
(Barton et al., 2016).
Researchers have yet to
discover the exact
trigger/cause of RA but it is
likely that genetics and
environmental causes play a
role in the development of RA
(Barton et al., 2016).
There is no cure for RA, merely
management of symptoms and
prevention of joint
deterioration (Barton et al.,
2016).

•

•

•

•

•

•

RA usually develops slowly over a
period of weeks to months before a
diagnosis by your Primary Care
Provider or NP is able to be made
(Rheumatoid Arthritis, 2014).
Classic symptoms that will present
include: pain, swelling and stiffness
of the peripheral joints and often
occur in the morning, lasting longer
than 6 weeks (Rheumatoid
Arthritis, 2014).
General systemic symptoms of
inflammation occur which include:
•
Fever
•
Fatigue
•
Weakness
•
Anorexia
•
Weight loss
•
Generalized aching
and stiffness
(Richards &
Edwards, 2014).
Pain early on in the disease process
occurs mainly from the pressure
created from swelling (Huether &
McCance, 2008).
Later on in the disease process,
pain occurs from abnormal
hardening of body tissue (sclerosis)
of the subchondral (layer of bone
just below the cartilage in a joint)
bone and new bone formation
(Huether & McCance, 2008).
The synovial joints affected are
usually symmetric in presentation
and when palpated are warm and
feel boggy with a ruddy, cyanotic
hue and thin shiny skin
(Rheumatoid Arthritis, 2014).

Pathophysiology
•

•

•

•

•

RA is a complex disease
process that can be best
characterized as an immune
mediated inflammatory
disease (Bingham, 2013).
In patients with normal
functioning immune systems,
the body’s self-antigens are in
a state of tolerance with the
host’s immune system. When
an autoimmunity response
occurs, the patient’s immune
system begins to recognize the
host’s self-antigens as foreign
(Huether & McCance, 2008).
Although researchers, do not
know the exact trigger that
induces a RA autoimmune
response, there is some data
that suggests the gene HLADR4 is involved (Bingham,
2013).
Even with some research that
points to a genetic cause of RA,
data has not been compiled
that supports one specific
trigger for the initiation of RA,
pointing to other factors in the
disease development (Barton
et al., 2016).
One of these other factors is a
bacterial or viral infection that
triggers an inflammatory
response, or modifiable risk
factors such as cigarette
smoking that induces
inflammation of the cells
(Bingham, 2013).

Significance of
Pathophysiology

Pathophysiology continued
•

•

•

•

RA is associated with class II major
histocompatibility (MHC) antigens.
When there is a deficiency of MHC
class II molecules, a decrease in the
recruitment of T- helper cells is
seen, which affects the host’s
normal antibody response
(Bingham, 2013).
T-helper cell’s responsibilities
include the antigen- driven
development of both B and T cells
(Huether & McCance, 2008).
Because the body is not able to
properly form an attack against the
antigen (whether foreign or self),
the inflammatory cascade is
initiated.
As stated by Huether and McCance
(2008), “The phagocytes of
inflammation ingest the immune
complexes and, in the process of
doing so, release powerful enzymes
that degrade synovial tissue and
articular cartilage” (p. 1049).

•
1.

2.

3.

The damage occurs primarily from
three functions:
Macrophages, neutrophils and other
phagocytes of inflammation in the
synovial fluid become activated,
degrading the cartilage (Bingham,
2013).
Cytokines stimulate synthesis of
proinflammatory compounds. Many
cytokines are present including
tumor necrosis factor (TNF),
interleukin (IL)-1, IL-6 and IL-8.
These cytokines effects include:
upregulation of adhesions
molecules, activation of osteoclasts,
induction of other inflammatory
mediators and activation of B-cells
among other things. These
proinflammatory compounds cause
chondrocytes to attack the cartilage
(Bingham, 2013).
Activation of B-lymphocytes cause
the production of more
autoantibodies such as rheumatoid
factor (RF) and anti-citrullinated
peptide antibody (ACPA). While Tlymphocytes produce enzymes that
amplify and perpetuate the
inflammatory response, creating a
never ending cycle of destruction
(Bingham, 2013).

•

•

1.

2.
3.
4.
5.
6.

•

Image 2. Illustrates the complex cellular process that occurs in RA

•
Image 1. Shows the different stages of RA and their physical presentation

•

•
(Rheumatoid Arthritis, n.d.)

(Arend, 2001)

Understanding the pathophysiology
of RA will help providers create a
unique treatment plan that is
tailored to the patient. Because RA
is an inflammatory and an immune
mediated disease there are different
drugs that can be utilized to prevent
symptoms of progression of
cartilage and bone destruction.
The 2015 American College of
Rheumatology developed guidelines
that address 6 major topics for
treatment of RA which include
Use of traditional diseasemodifying antirheumatic drugs
(DMARDs), biologic DMARDs, and
tofactinib.
Utilizing glucocorticoids.
Combination use of traditional
and biologic DMARDs in patients
with serious co-morbidities.
Using vaccines in patients before
they start treatment of traditional
or biologic DMARDS.
Screening for tuberculosis before
starting treatment.
Frequent laboratory monitoring
for patients who are prescribed
traditional DMARDs.
(Singh et al., 2015).
DMARDs work to suppress an
overactive immune system (Palmer
& Miedany, 2013). This can slow or
stop the progression of joint
damage seen from the
inflammatory and autoimmune
cascades outlined in the
pathophysiology section.
Biologic DMARDs are suggested for
treatment of patients with RA who
are not responding to traditional
DMARD therapy. Biologic DMARDs
are TNF inhibitors which have
shown to be effective in preventing
joint damage and halting the
inflammatory response (Palmer &
Miedany, 2013).
As stated by Palmer and Miedany
(2013), “Enhanced understanding
of the pathophysiology of RA and
the role of cytokines has enabled
the development of innovative
biological agents that target specific
parts of the immune response” (p.
317).
This is why understanding the
pathophysiology of RA is so vital to
NPs and APPs who will develop
treatment plans for their patients.

Implications for Nursing
The role of NPs in managing and
diagnosing patients with RA are expected
to increase over the next 10-20 years
(Riley et al., 2017). Yet a survey
conducted by Riley et al. (2017), showed
that NP’s had a low to moderate level of
confidence when diagnosing RA and a
low level of confidence in managing and
implementing treatment for patients
with RA. This is concerning as NP’s
working in primary care may potentially
be the first line for diagnosis of these
patients.
This knowledge gap shows that
increased training and education in RA
could help improve NPs awareness of the
signs and symptoms of RA, leading to an
earlier initiation of treatment or a
referral to a Rheumatologist (Riley et al.,
2017).
As this disease process is incurable, it
is also important for nurses to consider
the emotional impact that RA takes on
their patient’s lives. RA, as outlined
previously, causes pain, deformity,
fatigue and decreased physical function.
These symptoms can cause emotional
burden to patients, and it is crucial for
nurses to assess the health-related
quality of life (HRQL) of their patients
when assessing treatment efficacy
(Strand, Wright, Bergman, Tambiah &
Taylor, 2015).
Treatment of RA, from a patient’s
perspective, went beyond disease
management. Patients wanted a targeted
approach to disease management that
incorporated goal setting ( Strand et al.,
2015). Patients found that setting goals
allowed them to assess treatment
success and made them feel more
positive (Strand et al., 2015). Nurses
have the ability to help patient’s set these
goals and encourage discussion with
their APPs.

Conclusion
Rheumatoid Arthritis is an
immune mediated inflammatory
disease of unclear etiology. The
disease process primarily affects
the synovial joints of the hands and
feet and presents in a symmetric
presentation (Rheumatoid Arthritis,
2014). The presence of
autoantibodies perpetuates the
inflammatory cascade which causes
joint pain, swelling and if left
untreated deformity. Studies have
shown that early intervention is
critical for patients receiving
optimal outcomes (Rheumatoid
Arthritis, 2017).
Nurse Practitioners, especially
in the primary care setting, will
potentially be first line access to a
healthcare professional with
patients who are newly diagnosed
or have established RA (Riley et al.,
2017). Education in RA and RA
treatment is important for NPs in
optimizing the management of RA.
Overall, RA is an insidious
disease process, that can not be
prevented but can be managed to
prevent long-term disability and
improved patient outcomes.
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